Ads
related to: new treatment for neuropathy 2024 in ohio chart of diseasesbenchmarkguide.com has been visited by 10K+ users in the past month
helperwizard.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Peripheral neuropathy may be classified according to the number and distribution of nerves affected (mononeuropathy, mononeuritis multiplex, or polyneuropathy), the type of nerve fiber predominantly affected (motor, sensory, autonomic), or the process affecting the nerves; e.g., inflammation (), compression (compression neuropathy), chemotherapy (chemotherapy-induced peripheral neuropathy).
Anti-MAG peripheral neuropathy is a specific type of peripheral neuropathy in which the person's own immune system attacks cells that are specific in maintaining a healthy nervous system. As these cells are destroyed by antibodies , the nerve cells in the surrounding region begin to lose function and create many problems in both sensory and ...
Treatment Occupational therapy, weight decrease (management) [ 1 ] Polyneuropathy (from Greek poly- 'many' neuro- 'nerve' and -pathy 'sickness') is damage or disease affecting peripheral nerves ( peripheral neuropathy ) in roughly the same areas on both sides of the body, featuring weakness , numbness , and burning pain. [ 1 ]
Corticosteroid responsive optic neuritis not associated with demyelinating disease should also be ruled out, including sarcoidosis, systemic lupus erythematosus, or other systemic autoimmune disease. [11] Hereditary causes such as Leber's hereditary optic neuropathy are also part of the differential diagnosis. [12]
NAION is characterized by localized disruptions in blood flow to the optic nerve, often linked with broader systemic vascular conditions. Key risk factors include coronary artery disease, cerebrovascular disease, sleep apnea, diabetes, and hypertension. Currently, there is no universally accepted, scientifically proven treatment for NAION.
The characteristics are typical of demyelinating neuropathy with antimyelin-associated glycoprotein (MAG) antibodies; however, anti-MAG neuropathy is not included in the CIDP criteria according to the EFNS/PNS criteria, primarily due to the presence of a particular antibody and a different response to treatment.
Ads
related to: new treatment for neuropathy 2024 in ohio chart of diseasesbenchmarkguide.com has been visited by 10K+ users in the past month
helperwizard.com has been visited by 10K+ users in the past month